Last reviewed · How we verify
Gefitinib, radiotherapy
At a glance
| Generic name | Gefitinib, radiotherapy |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer (PHASE1)
- A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer
- Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer (PHASE2)
- Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma (NA)
- Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer (PHASE2)
- Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) (PHASE3)
- Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme (PHASE1, PHASE2)
- Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gefitinib, radiotherapy CI brief — competitive landscape report
- Gefitinib, radiotherapy updates RSS · CI watch RSS
- AstraZeneca portfolio CI